Table 4.
Mean radiation dose for HRCTV and OARs according to fistula status (dose – volume parameters [DVH] patients and Gy)
| Variable | Fistula | No fistula | p-value |
|---|---|---|---|
| CHT (absolute number of cycles) | 2 | 23 | 0.043a |
| CHT + BEV (absolute number of cycles) | 4 | 6 | – |
| Mean HRCTV D90 (%) | 92.1 (5.0) | 89.7 (7.4) | 0.353b |
| Mean D0.1cc rectum (%) | 78.0 (4.6) | 72.4 (11.1) | 0.060b |
| Mean D2cc rectum (%) | 62.8 (7.8) | 66.9 (3.6) | 0.066b |
| Mean D0.1cc bladder (%) | 100.2 (12.6) | 101.2 (7.9) | 0.806b |
| Mean D2cc bladder (%) | 82.1 (6.7) | 80.2 (8.1) | 0.551b |
| Mean D0.1 sigmoid (%) | 69.3 (12.5) | 80.5 (11.6) | 0.084b |
| Mean D2cc sigmoid (%) | 59.4 (8.8) | 66.5 (6.4) | 0.108b |
| Mean D0.1 bowel (%) | 69.2 (20) | 57 (16) | 0.193b |
| Mean D2cc bowel (%) | 58 (9) | 53 (10) | 0.278b |
| No. of CHT cycles (%) | 5.2 (2.2) | 5.6 (3.0) | 0.715b |
| No. of BEV cycles (%) | 3.8 (1.7) | 6.5 (4.3) | 0.200b |
CHT chemotherapy, BEV bevacizumab, HRCTV high-risk clinical target volume, D90 dose to 90% of the HRCTV, OAR organ at risk, D0.1cc dose to 0.1cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder), D2cc dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)
aχ2 test
b t-test